Pyxis Oncology's MICVO Shows 36% ORR and 94% DCR in Updated Phase 1 HNSCC Data
PYXS has more than doubled off its 52-week low of $1.03.
Summary
Pyxis Oncology reported updated Phase 1 data for MICVO in 2L+ R/M HNSCC, showing a 36% confirmed objective response rate and 94% disease control rate in 33 efficacy-evaluable patients. Median progression-free survival was 6.2 months and 12-month overall survival probability was 79%, with no new safety signals. The company plans to initiate a Phase 3 Headliner trial in mid-2027 following an End of Phase 2 meeting with the FDA in Q1 2027. This follows the Q2 2026 update and the recent appointment of Thomas Civik as permanent CEO. The data support advancement to a pivotal program and could significantly de-risk the lead asset.
At the time of this announcement, PYXS was trading at $4.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $324.5M. The 52-week trading range was $1.03 to $5.55. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.